Sympathetic hyperactivity influences chemosensor function in patients with end-stage renal disease

European Journal of Medical Research

Volumn 14, Issue SUPPL.4, 2009, Pages 151-155

  Meyer, C ^a   Schueller, P ^a   Balzer, J ^a   Lauer, T ^a   Westenfeld, R ^a   Schauerte, P ^b   Hennersdorf, M ^c   Steiner, S ^a   Kelm, M ^a   Rassaf, T ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c SLK Kliniken Heilbronn   (Germany)

Author keywords

chemoreflexes; end stage renal disease; nervous system; sympathetic

Indexed keywords

ADRENERGIC SYSTEM; AGED; ARTICLE; CHEMORECEPTOR; CHRONIC KIDNEY FAILURE; FEMALE; HUMAN; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; REFLEX;

AGED; CHEMORECEPTOR CELLS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; REFLEX; SYMPATHETIC NERVOUS SYSTEM;

EID: 77955485960     PISSN: 09492321     EISSN: 2047783X     Source Type: Journal    
DOI: 10.1186/2047-783X-14-S4-151     Document Type: Article

References (21)

1. Renal and cardiovascular predictors of 9-year total and sudden cardiac mortality in non-insulin-dependent diabetic subjects. Wirta O, Pasternack A, Mustonen J, Laippala P, Nephrol Dial Transplant 1997 12 2612 7 10.1093/ndt/12.12.2612 9430860 (Pubitemid 27520683)
2. Sympathetic overactivity in patients with chronic renal failure. Converse RL Jr, Jacobsen TN, Toto RD, et al. N Engl J Med 1992 327 1912 8 10.1056/NEJM199212313272704 1454086 (Pubitemid 23006966)
3. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. Ligtenberg G, Blankestijn PJ, Oey PL, et al. N Engl J Med 1999 340 1321 8 10.1056/NEJM199904293401704 10219067 (Pubitemid 29196594)
4. Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment. Neumann J, Ligtenberg G, Klein II, Koomans HA, Blankestijn PJ, Kidney Int 2004 65 1568 76 10.1111/j.1523-1755.2004.00552.x 15086894 (Pubitemid 38591003)
5. Sympathetic nerve activity in end-stage renal disease. Hausberg M, Kosch M, Harmelink P, et al. Circulation 2002 106 1974 9 10.1161/01.CIR.0000034043. 16664.96 12370222 (Pubitemid 35176304)
6. Tonic chemoreflex activation contributes to the elevated muscle sympathetic nerve activity in patients with chronic renal failure. Hering D, Zdrojewski Z, Krol E, et al. J Hypertens 2007 25 157 61 10.1097/HJH. 0b013e3280102d92 17143187 (Pubitemid 44885677)
7. Hyperoxia lowers sympathetic activity at rest but not during exercise in humans. Seals DR, Johnson DG, Fregosi RF, Am J Physiol 1991 260 873 R878 2035699
8. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, Ann Intern Med 1999 130 461 70 10075613 (Pubitemid 29135798)
9. Chemoreflex sensitivity in chronic heart failure patients. Hennersdorf MG, Hillebrand S, Perings C, Strauer BE, Eur J Heart Fail 2001 3 679 84 10.1016/S1388-9842(01)00189-1 11738219 (Pubitemid 33121344)
10. Chemoreflex sensitivity as a predictor of arrhythmia relapse in ICD recipients. Hennersdorf MG, Niebch V, Perings C, Strauer BE, Int J Cardiol 2002 86 169 75 10.1016/S0167-5273(02)00191-2 12419553 (Pubitemid 35284805)
11. Chemoreflex sensitivity among patients with paroxysmal atrial fibrillation. Budeus M, Hennersdorf M, Perings C, Z Kardiol 2003 92 558 63 10.1007/s00392-003-0952-1 12883840 (Pubitemid 36898134)
12. Effect of end-stage renal disease on decreased heart rate variability. Steinberg AA, Mars RL, Goldman DS, Percy RF, Am J Cardiol 1998 82 1156 8 A10 10.1016/S0002-9149(98)00580-3 9817506 (Pubitemid 28507111)
13. Alteration of heart rate variability parameters in nondiabetic hemodialysis patients. Tong YQ, Hou HM, Am J Nephrol 2007 27 63 9 10.1159/000099013 17259695 (Pubitemid 46364542)
14. Autonomic dysfunction in uremia assessed by heart rate variability. Tory K, Suveges Z, Horvath E, et al. Pediatr Nephrol 2003 18 1167 71 10.1007/s00467-003-1280-4 13680330 (Pubitemid 37406867)
15. Cardiac autonomic neuropathy in patients with chronic renal failure on hemodialysis. Kurata C, Uehara A, Sugi T, et al. Nephron 2000 84 312 9 10.1159/000045605 10754407 (Pubitemid 30179455)
16. Augmentation of chemosensitivity during mild exercise in normal man. Weil JV, Byrne-Quinn E, Sodal IE, Kline JS, McCullough RE, Filley GF, J Appl Physiol 1972 33 813 9 4643864
17. Chemoreflexsensitivity in patients with survived sudden cardiac arrest and prior myocardial infarction. Hennersdorf MG, Perings C, Niebch V, Hillebrand S, Vester EG, Strauer BE, Pacing Clin Electrophysiol 2000 23 457 62 10.1111/j.1540-8159.2000.tb00827.x 10793434 (Pubitemid 30226913)
18. Hyperoxic chemoreflex sensitivity is impaired in patients with neurocardiogenic syncope. Meyer C, Rana OR, Saygili E, et al. Int J Cardiol 2009
19. Differential activation of cardiac and peripheral sympathetic nervous system by nifedipine: role of pharmacokinetics. Wenzel RR, Allegranza G, Binggeli C, et al. J Am Coll Cardiol 1997 29 1607 14 10.1016/S0735-1097(97) 00095-8 9180126 (Pubitemid 27272457)
20. Sympathetic outflow to muscles during treatment of hypertension with metoprolol. Wallin BG, Sundlof G, Stromgren E, Aberg H, Hypertension 1984 6 557 62 10.1161/01.HYP.6.4.557 6378790 (Pubitemid 14067811)
21. Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure. Neumann J, Ligtenberg G, Oey L, Koomans HA, Blankestijn PJ, J Am Soc Nephrol 2004 15 2902 7 10.1097/01.ASN. 0000143471.10750.8C 15504943 (Pubitemid 41103399)